In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjögren's syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with PD-1 inhibition (pembrolizumab).

中文翻译：

---

肺癌患者中由 PD-1 抑制引起的干燥综合征。

在本报告中，我们介绍了一名转移性非小细胞肺癌患者，由于免疫检查点抑制继发了干燥综合征。该患者具有典型的临床表现和生化特征，是在开始 PD-1 抑制剂（pembrolizumab）治疗后仅 18 个月出现的。